Our purpose in this study was to evaluate the new JAS guidelines as a risk assessment tool in Japanese patients with hypercholesterolemia, using the cohort of the Holicos-PAT study. The Holicos-PAT study was designed as a prospective observational study. 2039 patients were followed with or without pravastatin for 5 years. We assessed coronary heart disease (CHD) and cerebrovascular disease (CVD) risks by the patient categories described in the JAS guidelines. In the Holicos-PAT study, the primary endpoints were CHD, and the secondary endpoints were CVD and total mortality. CHD event includes onset and worsening of angina pectoris, performing CABG or PTCA, non-fatal and fatal myocardial infarction, and death from CHD including heart death and sudden death. CVD events are onset or recurrence of cerebral infarction, onset of cerebral hemorrhage, and death from cerebral infarction or hemorrhage. The event rates were calculated by the person-years method, and the differences in event rates between category groups were analyzed by chi-square test. The event rates of CHD in Category A, B1, B2, B3, B4 and C, were 1.1, 4.0, 2.8, 5.7, 18.2 and 38.8 per 1,000 person-years. The rates of CHD events in the higher risk category groups, Category B4 group (p = 0.004 in whole patients) and C group (p < 0.001 in whole patients), were significantly higher than that in the combined category groups A + B1 + B2. The event rates of CVD in Category A, B1, B2, B3, B4 and C, were 2.1, 1.8, 1.8, 0.6, 10.8 and 6.4 per 1,000 person-years. The event rates of CHD in men were significantly higher than those in women, in categories B4 (p < 0.001) and C (p < 0.001). From these results, each category classified by accumulation of risk factors, showed increasing event rates of CHD and CVD. The categories in the JAS guidelines are useful to assess CHD and CVD risk in Japanese patients with hypercholesterolemia. However, the risk evaluation by the JAS guideline categories may underestimate the risk in men and overestimate it in women. J Atheroscler Thromb, 2005; 12: 48-52.
Introduction
The Japanese Atherosclerosis Society (JAS) published new guidelines for the diagnosis and treatment of atherosclerotic cardiovascular diseases in 2002 (1, 2) . Hypercholesterolemia is one of the major risk factors that contributes to the development of coronary atherosclerosis (3) . Recent clinical practice guidelines recommend that physicians and patients make decisions regarding coronary heart disease (CHD) prevention on assessment of underlying global CHD risk (3) (4) (5) (6) (7) (8) (9) .
It has been reported that the incidence of CHD is lower in Japanese, compared with North American and European peoples (10, 11) . The Japan Lipid Intervention Trial (J-LIT) was undertaken and reported in 2002 (12, 13) . The J-LIT involved 52,421 patients with simvastatin treatment, and the results showed a positive relationship between LDL-C levels and CHD events, and a negative relationship between HDL-C levels and CHD events. The results from the studies in Japan such as the Hisayama study (14) , NIPPON DATA (15) , KLIS (16) as well as those from J-LIT, were incorporated into the new JAS guidelines, considering the clinical decision making according to the person's absolute risk.
Our purpose in this study is to evaluate the JAS guidelines as a risk assessment tool in Japanese patients with hypercholesterolemia, using the cohort of the Holicos-PAT study (17) . The Holicos-PAT study was designed in 1989 in the Hokuriku district, as a prospective observational study. 2039 patients were followed with or without pravastatin for 5 years. The primary endpoints were CHD, and the secondary endpoints were CVD and total mortality. CHD event includes onset and worsening of angina pectoris in the Holicos-PAT, in contrast to the other studies.
Patients and Methods
We assessed CHD and cerebrovascular disease (CVD) risks by the patient categories, in the 2,039 patients of Holicos-PAT study. The main outcome measures were CHD events and CVD events, identified in the Holicos-PAT study. The event rates were calculated by the person-years method. The patient category was described in the JAS guidelines. In brief, Category A is absence of CHD and absence of atherosclerosis risk factors other than hypercholesterolemia, B1, B2, B3 and B4 are absence of CHD but presence of one to four atherosclerosis risk factors other than hypercholesterolemia, and C is presence of CHD.
The results of the Holicos-PAT study are described in full elsewhere (17) . The patients with hypercholesterolemia (total cholesterol was greater than 220 mg/dl) were registered, and followed up by 132 physicians at 70 facilities. 2,232 patients were recruited and 193 patients were excluded. 1290 patients received pravastatin and 749 patients were followed without pravastatin (Diet group) for 5 years. Baseline characteristics are shown in Table 1 . About 60% were women, and the mean age was 56.8 years. Hypertension was present in 37% and diabetes mellitus in about 15%. 82% had no history of CHD, and 18% had a history of CHD. The primary endpoints were CHD, and the secondary endpoints were CVD and total mortality. Coronary heart event includes onset and worsening of angina pectoris, performing CABG or PTCA, non-fatal and fatal myocardial infarction, and death from CHD including heart death and sudden death. Cerebrovascular events: CVD events are onset or recurrence of cerebral infarction, onset of cerebral hemorrhage, and death from cerebral infarction or hemorrhage.
Statistical Analysis
As for the incidence of events, the number of occurrences per 1,000 patients-years was calculated. Data of the patients with or without pravastatin treatment were combined in the groups of whole patients, men and women, because there were no significant differences in the event rates between them that was described in the previous paper (17) . Baseline imbalances were compared between men and women by using either t test or chisquare test according to the type of variables. In comparisons of the event rates with person-year data between two groups, chi-square test assuming a Poisson model was used. The significance level was 5%, and the statistical package SAS version 6.12 (SAS Institute, NC) was used.
Results
The patient background was shown in Table 1 . There were the significant differences between men and women, in the variables of age (p < 0.001), angina pectoris (p < 0.001), myocardial infarction (p < 0.001), cerebral infarction (p = 0.022), hypertension (p = 0.002), diabetes mellitus (p < 0.001), current smoking (p < 0.001), body mass index (p < 0.001) and serum lipids (p < 0.001). LDL-C and HDL-C levels in men were significantly lower than those in women (p < 0.001), but triglyceride level in men was significantly higher than that in women (p < 0.001). The percent pravastatin treatment in men (56.9%) was significantly lower than that in women (67.1%) (p < 0.001). The number of patients in each category group was shown in Table 2 . The percent secondary prevention, Category C was 18%. Category B4 was only 123 patients.
In the whole patients group, the event rates of CHD in Category A, B1, B2, B3, B4 and C, were 1.1, 4.0, 2.8, 5.7, 18.2 and 38.8 per 1,000 person-years (Table 3) . When the event rates of CHD in the Category B4 and C groups were compared to that in the combined category groups A + B1 + B2, the rates of CHD events in the higher risk category groups, Category B4 group (p = 0.004 in whole patients) and C group (p < 0.001 in whole patients), were significantly higher than that in the lower risk category group. The event rates of CHD in men were significantly higher than those in women, in the category B4 (p < 0.001) and C (p < 0.001).
The event rates of CVD in Category A, B1, B2, B3, B4 and C, were 2.1, 1.8, 1.8, 0.6, 10.8 and 6.4 per 1000 person-years, in the whole patients group (Table 4) . When the event rates of CVD in the category B4 and C groups were compared to that in the combined category groups A + B1 + B2, the rates of CVD events in the higher risk category groups: Category B4 group (p = 0.027 in whole patients) and C group (p = 0.142 in whole patients), were higher than that in the lower risk category group. The event rates of CVD in men showed the same tendency as those in women.
Discussion
This study examined the risk of CHD and CVD in Japanese patients with hypercholesterolemia, classified by the categories in JAS guidelines, using the cohort of the Statistical differences between men and women are shown by P values: *p < 0.05, **p < 0.01, ***p < 0.001. Diet: the patients with diet only therapy. Holicos-PAT study. The JAS guidelines reported the absolute and relative risk of CHD classified by accumulation of risk factors, calculated according to the data from J-LIT. In J-LIT, the relative rate of CHD is 2 in one risk factor group, 4 in two risk factors group, 8 in three risk factors group, and 15 in four risk factors group (1). The relative risk of CHD from the Holicos-PAT is 4 in one risk factor group, 3 in two risk factors group, 5 in three risk factors group, and 17 in more than four risk factors group. The relative risk was similar between the two trials. The absolute risk was not compared directly, because of the different endpoints. The endpoints in Holicos-PAT include the onset and worsening of angina pectoris, but the J-LIT does not include these. Angina pectoris accounted for 49.5% of the whole CHD events. In the Holicos-PAT study, CHD events occurred in 55.4 per 1,000 patientsyear for men and 23.6 per 1,000 patients-year for women with a history of CHD, and myocardial infarction occurred in 8.4 per 1,000 patients-year for men, and 5.7 per 1,000 patients-year for women with a history of CHD (17) . CHD events including nonfatal/fatal myocardial infarction and cardiac sudden death in the J-LIT, was 4.45 per 1,000 patients-year in the patients with a history of CHD (12) . The interpretation of the results from the Holicos-PAT may be limited, because of the small number of the events. The incidence of CHD events was 3.5 times higher than that of CVD events in this study. The CVD event rate in the Holicos-PAT (3.0 per 1,000 patients-year in whole patients) was lower than that in the KLIS (5.2 per 1,000 patients-year in the control group). CHD and CVD event rates in the KLIS showed 6.0 and 5.2 per 1,000 patientsyear in the control group, respectively, in a 5-year follow-up (16) . There were 249 deaths from CHD, and 174 deaths from CVD in Nippon Data (15) . The difference may be accounted by the different endpoints: the endpoints in KLIS did not include onset and worsening of angina pectoris. From other points, the events of CVD were defined in Holicos-PAT as the onset and recurrence of cerebral infarction, the onset of cerebral hemorrhage, or death from the clinical findings and CT scanning. The events of CVD may have been underestimated because of lack of autopsy. The number of CHD death gradually increased, in comparison with CVD death, in Japan.
Current guidelines in the world recommend lipid-lowering therapy by specific drugs, if the absolute risk exceeds a certain threshold (18) . The threshold is 20% over 10 years according to the joint European Societies guidelines (4, 5) and 15% over 10 years according to the joint British guidelines (6) . Most Japanese patients are of low risk for CHD, but 16% of Japanese die of cardiac disease, and 13% of cerebrovascular disease (19) . The number of CHD deaths has exceeded that of CVD deaths, since 1990. As a result, substantial number of Japanese die of atherosclerotic diseases. To make a strategy for prevention of the atherosclerotic diseases in Japan, we have to consider the traits in patient preference regarding the lipid-lowering therapy and cost-effectiveness.
Various guidelines use different risk assessment methods. There are a lot of Framingham-based risk calculation tools (20) . The Framingham Scores, originally developed in a white, middle-class population, overestimated CHD risk in Japanese-American and Hispanic men and Native American women (10) . These results suggest that the Framingham Score should be used after recalibration, which requires data on each cohort's CHD risk factor prevalence and CHD event rates (11) .
The event rate of CHD was analyzed in the male and female groups. The event rate of CHD in men was higher than that in women, even though the factor of gender was considered when the patients were categorized. The factor of gender may be more potent than one risk factor for CHD, and the risk may be underestimated in men and overestimated in women. We have to consider the differences between men and women when using the JAS guidelines. From these results, we thought that the categories in the Japanese guidelines are useful to assess CHD and CVD risk in Japanese patients with hypercholesterolemia. Statistical differences between men and women are shown by P values: *p < 0.05, **p < 0.01, ***p < 0.001. Statistical differences of category B3, B4 and C, to the combined category groups A + B1 + B2, are shown by P values: † p < 0.05, ¶ p < 0.01, § p < 0.001, ns no significance. Numbers are per 1,000 person-years.
